ResMed (RMD) : Traders are bullish on ResMed (RMD) as it has outperformed the S&P 500 by a wide margin of 5.65% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.98%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.41% in the last 1 week, and is up 8.28% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
ResMed (NYSE:RMD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $69.45 and $69.41 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $69.97. The buying momentum continued till the end and the stock did not give up its gains. It closed at $69.85, notching a gain of 1.09% for the day. The total traded volume was 935,828 . The stock had closed at $69.10 on the previous day.
The stock has recorded a 20-day Moving Average of 5.45% and the 50-Day Moving Average is 11.25%. ResMed Inc. is up 24.31% in the last 3-month period. Year-to-Date the stock performance stands at 31.47%.
ResMed (RMD) : 7 Wall Street analysts covering ResMed (RMD) believe that the average level the stock could reach for the short term is $60.86. The maximum price target given is $70 and the minimum target for short term is around $50, hence the standard deviation is calculated at $7.48.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.